NCT01648270View on ClinicalTrials.gov

Buprenorphine Disposition and Cyclosporine

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Healthy
Interventions
DRUG

buprenorphine

Session 1 Intravenous buprenorphine: 0.2 mg over 1 hr Session 2 Sublingual buprenorphine: 2 mg Session 3 Intravenous buprenorphine 0.2 mg over 1 hr beginning 1 hr after starting cyclosporine Session 4 Sublingual buprenorphine: 2 mg after cyclosporine.

Trial Locations (1)

63012

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT01648270 - Buprenorphine Disposition and Cyclosporine | Biotech Hunter | Biotech Hunter